Objective: Availability of closed-loop insulin delivery systems is expected by patients with type 1 diabetes. Our main objective was to assess whether patients using the Diabeloop artificial pancreas system could achieve a better glucose control compared to sensor-assisted pump therapy, as measured by percentage time in range 70-180 mg/dl.

Methods: A multicenter clinical trial was conducted in a home setting, using an MPC-based algorithm, a hybrid monohormonal system (CellNovo® pump and Dexcom G5® sensor) and centralised remote monitoring. Adult patients with T1D for ≥ 2 years, pump therapy for ≥ 6 months, HbA1c ≤ 10%, and preserved hypoglycemia awareness were included among 12 investigation centers. Design was a crossover trial with a 2-week run-in period, followed by 2 sequences of 12 weeks each separated with washout. Results of the first 12-week arm are reported.

Results: 68 patients (27 men, age 47.2±13.4 years, HbA1c 7.6±0.9%, duration of disease 27.9±13.2 years) were randomised between closed-loop (CL, n=33) and open-loop (OL, n=35) first. During the first 12-week period, time spent in the 70-180 mg/dl range was 69.5% [62.4;75.6] in CL vs. 58.7% [45.2;64.9] in OL. Time in hypoglycaemia <70 mg/dl was 2.1% [1.2;2.6] in CL vs. 4.1% [1.9;6.1] in OL.

Conclusion: The Diabeloop closed-loop system was efficient regarding metabolic outcomes.

Disclosure

S. Franc: Consultant; Self; Animas Corporation, Roche Diabetes Care Health and Digital Solutions, Johnson & Johnson Diabetes Institute, LLC. P.Y. Benhamou: Consultant; Self; Abbott, Sanofi, Novo Nordisk Inc.. Other Relationship; Self; Eli Lilly and Company, Roche Diabetes Care Health and Digital Solutions. Advisory Panel; Self; Diabeloop S.A. S. Borot: Consultant; Self; Abbott, Animas Corporation, Johnson & Johnson Diabetes Institute, LLC., Medtronic, Roche Diabetes Care Health and Digital Solutions. L. Chaillous: None. B. Delemer: Other Relationship; Self; Sanofi-Aventis, Eli Lilly and Company. B. Guerci: None. H. Hanaire: Consultant; Self; Abbott, Animas Corporation, Johnson & Johnson Diabetes Institute, LLC., Medtronic, Roche Diabetes Care Health and Digital Solutions. N.M. Jeandidier: Board Member; Self; Sanofi-Aventis. E. Renard: Advisory Panel; Self; Abbott. Board Member; Self; Eli Lilly and Company, Insulet Corporation, Novo Nordisk A/S, Sanofi, Roche Pharma. Consultant; Self; Air Liquide. Research Support; Self; Roche Pharma, Dexcom, Inc., TypeZero Technologies, Inc.. Y. Reznik: None. P. Schaepelynck: Consultant; Self; Roche Diabetes Care Health and Digital Solutions. Speaker's Bureau; Self; Medtronic MiniMed, Inc.. Board Member; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Sanofi-Aventis, Abbott, Eli Lilly and Company. C. Thivolet: Advisory Panel; Self; Abbott, Sanofi-Aventis, Medtronic MiniMed, Inc. G. Charpentier: Consultant; Self; Abbott, Dexcom, Inc., Medtronic.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.